title: Effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in rats.
abstract: The present study was designed to investigate the protective effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in albino rats. Methionine (1 g/kg, orally) administration to pathogenic control rats (i.e. group II) for 30 days significantly (P < 0.01) increased the levels of homocysteine, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) and triglycerides (TGs) and decreased the levels of high-density lipoprotein cholesterol (HDL-C) in serum. Haematological observations of the peripheral blood smears of pathogenic rats (i.e. group II) fed with methionine also showed crenation of red blood cells cell membrane and significant (P < 0.01) increase in total leucocyte count, differential leucocyte count and platelet counts with significant (P < 0.01) decrease in the mean haemoglobin levels as compared to vehicle control rats (group I). Administration of rosuvastatin (0.5 mg/kg/day, orally) to hyperhomocysteinaemic rats for 30 days significantly (P < 0.01) decreased the levels of homocysteine, TC, TGs, LDL-C, VLDL-C and increased the levels of HDL-C in serum. The present results provide clear evidence that oral treatment with rosuvastatin produces homocysteine and lipid lowering activity and also reversal of haematological changes induced by methionine in rats.
authors.affiliation: Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard University, New Delhi, India.
authors.forename: Gaurav Kumar
authors.initials: GK
authors.lastname: Nigam
authors.forename: M Nazam
authors.initials: MN
authors.lastname: Ansari
authors.forename: Uma
authors.initials: U
authors.lastname: Bhandari
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006403:Hematologic Tests; D006454:Hemoglobins / Q000032:analysis; D020138:Hyperhomocysteinemia / Q000097:blood* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D008715:Methionine; D010976:Platelet Count; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D005464:Fluorobenzenes; D006454:Hemoglobins; D000960:Hypolipidemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D008715:Methionine